HNB
ZYNE

Huntington National Bank’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Huntington National Bank’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-217
Closed -$93 – 3842
2023
Q1 		$93 Hold
217
– – ﹤0.01% 2230
2022
Q4 		$115 Hold
217
– – ﹤0.01% 2052
2022
Q3 		$0 Hold
217
– – ﹤0.01% 2498
2022
Q2 		$0 Hold
217
– – ﹤0.01% 2506
2022
Q1 		$0 Hold
217
– – ﹤0.01% 2445
2021
Q4 		$0 Buy
+217
New +$803 ﹤0.01% 2378

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BWP
Bernardo Wealth Planning Harleysville, Pennsylvania $585M AUM 17.72% 1-Year Est. Return

Huntington National Bank's ZYNE Position: Q2 2023 in Review

Huntington National Bank sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2023, closing a stake of 217 shares — an estimated $93 sold.

Huntington National Bank first reported a position in ZYNE in Q4 2021 and held it in 6 quarters. The position peaked at $115 in Q4 2022. 41 funds tracked by Wall St. Rank hold ZYNE as of Q2 2023.

  • Huntington National Bank reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2023 after selling out during the quarter.
  • Huntington National Bank sold 217 Zynerba Pharmaceuticals, Inc shares in Q2 2023, an estimated $93.
  • Huntington National Bank first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2021 and held it in 6 quarters.
  • Huntington National Bank's Zynerba Pharmaceuticals, Inc position peaked at $115 in Q4 2022.
  • 41 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2023.

Based on Huntington National Bank's 13F filing for Q2 2023, filed 11 Aug 2023.